The public offering of shares by ReShape Lifesciences at $0.33 per share could lead to dilution of existing shareholders' equity. This is because the new shares increase the total number of outstanding shares, reducing the proportion of the company that each existing share represents. This could potentially lead to a decrease in the stock price.